Zyvox (linezolid) Use in Long Term Care
Zyvox (linezolid) is an antibiotic effective against a wide spectrum of gram-positive organisms, including resistant strains such as methicillin-resistant staphylococcus (MRSA) and vancomycin-resistant enterococci (VRE). It is often the topic of pharmacy recommendations due to the potential of serious side effects, drug interactions, inappropriate use and cost.
Antibiotic Stewardship and Appropriate Use
Antibiotic stewardship is the term used to describe the process of selecting the optimal antibiotic medication, dose, duration of therapy, and route of administration.1 It requires that the most appropriate antibiotic be used in any given situation. Antibiotic stewardship decreases the likelihood of developing resistant organisms, maximizes cost effectiveness, and improves patient outcomes.
When applying the concept of antibiotic stewardship to Zyvox, we first need culture and sensitivity (C&S) results showing susceptibility to Zyvox. It is important to note that Zyvox is usually not appropriate for empiric therapy. Once susceptibility has been determined by C&S, Zyvox may be an appropriate antibiotic for treating a patient’s infection. Here are some examples of situations where Zyvox may be appropriate:
- The patient’s culture and sensitivity shows susceptibility to IV vancomycin and to Zyvox, but the patient is unable to tolerate IV vancomycin.
- The patient’s culture and sensitivity shows susceptibility to IV vancomycin and to Zyvox, but the IV access cannot be established.
- The patient’s culture and sensitivity shows vancomycin-resistant enterococcus (VRE) susceptible for Zyvox.
The following chart shows the indications for use of Zyvox in adult patients, along with the recommended dose and length of therapy. Courses of treatment longer than 28 days are not typical and increase the risk for additional side effects like lactic acidosis, peripheral neuropathy and optic neuropathy.2
Indication | Dose | Length of therapy |
Nosocomial pneumonia caused by Staph. aureus or MRSA | 600 mg IV or PO Q12 | 10-14 days |
Community-acquired pneumonia caused by Strep. pneumoniae or Staph. aureus | 600 mg IV or PO Q12 hours
|
10-14 days
|
Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staph. aureus, MRSA, or Strep. agalactiae | 600 mg IV or PO Q12 hours | 10-14 days |
Uncomplicated skin and skin structure infections caused by Staph. aureus or Strep. pyogenes | 400 mg PO Q12 hours | 10-14 days |
Vancomycin-resistant Enterococcus faecium (VRE) infections | 600 mg IV or PO Q12 hours | 14-28 days
|
Alternatives to Zyvox
Alternatives to Zyvox for treatment of MRSA may include IV vancomycin, daptomycin (Cubicin), and tigacycline (Tygacil), depending on the site of infection and the culture and sensitivity. IV vancomycin is by far the most cost-effective option, as Zyvox costs more than 10 times more than vancomycin. Zyvox is the only medication of this group to offer a PO route of administration (tablets and oral suspension).
Side Effects
Zyvox, like many antibiotics, can cause diarrhea, headache, nausea, and vomiting. However, when nausea and vomiting occurs with Zyvox, it may indicate lactic acidosis. Zyvox can also cause myelosuppression, including anemia, leukopenia, pancytopenia, and thrombocytopenia. Optic neuropathy is also a possible side effect, especially when Zyvox is used for longer than 28 days.
Serotonin Syndrome
Serotonin syndrome is a condition caused by excess serotonin in the body. It is the most significant drug-drug interaction involving Zyvox. Signs and symptoms of serotonin syndrome may include stiff muscles, confusion, racing heartbeat, diarrhea, nausea, vomiting, high fever, shivering, hallucinations, very high or very low blood pressure, large pupils or sweating.
Monitoring
LABS: Complete blood count (CBC) weekly, due to the risk of myelosuppression. This is particularly important in patients who already have myelosuppression or who have a history of myelosuppression.
Nursing: Nurses should monitor the patient’s blood pressure, heart rate, and temperature daily and monitor for the signs and symptoms of serotonin syndrome and other side effects.
Pharmacy Recommendations
AlixaRx pharmacists will issue a recommendation to the provider when Zyvox is ordered for a patient on a medication that may increase the risk of serotonin syndrome. Many of these medications are antidepressants. A more detailed list of these medications can be found at the end of this article.3 Recommendations may request that an alternative antibiotic be considered, that an interacting drug be held until Zyvox is completed, or that CBC or other lab monitoring be initiated.
The drug interactions and side effects of Zyvox are important to watch out for, but equally important is its place in treating MRSA and VRE infections. With proper antibiotic stewardship, patient monitoring, and a clear understanding the risks and benefits of Zyvox, we can help our patients recover as quickly as possible
I. Serotonergic psychiatric drugs implicated in the AERS cases of serotonin syndrome with linezolid
Selective Serotonin Reuptake Inhibitors (SSRIs)
Generic Name Found in Brand Names
Paroxetine Paxil, Paxil CR
Fluvoxamine Luvox, Luvox CR
Fluoxetine Prozac, Symbyax
Sertraline Zoloft
Citalopram Celexa
Escitalopram Lexapro
Vilazodone Viibryd
Although the FDA has not received cases of serotonin syndrome to date involving vilazodone, the pharmacology of this drug places it in the SSRI category and suggests that it possesses a risk comparable to that of the SSRIs.
Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Generic Name Found in Brand Names
Venlafaxine Effexor, Effexor XR
Desvenlafaxine Pristiq
Duloxetine Cymbalta
II. Other psychiatric drugs with varying degress of serotonergic activity for which the risk of serotonin syndrome with linezolid is unclear
Tricyclic Antidepressants (TCAs)
Generic Name Found in Brand Names
clomipramine Anafranil
amitriptyline Amitid, Amitril, Elavil, Endep, Etrafon,
amitriptyline
desipramine
imipramine
nortriptyline
doxepin Sinequan, Zonalon, Silenor
trimipramine Surmontil
Monoamine Oxidase Inhibitors (MAOIs)
Generic Name Found in Brand Names
isocarboxazid Marplan
phenelzine Nardil
transdermalselegiline Emsam
tranylcypromine Parnate
Other Psychiatric Medications
Generic Name Found in Brand Names
amoxapine Asendin
maprotiline Ludiomil
nefazodone Serzone
trazodone Desyrel, Oleptro, Trialodine
bupropion Wellbutrin, Wellbutrin SR, Wellbutrin XL, Aplenzin
buspirone Buspar
mirtazapine Remeron, RemeronSoltab
References:
- Infectious Diseases Society of America, Arlington, VA. http://www.idsociety.org/Stewardship_Policy/. Accessed September 2, 2015.
- Zyvox [package insert]. Pharmacia & Upjohn Co, New York, NY; June 2015. http://www.labeling.pfizer.com/showlabeling.aspx?id=649#section-2. Accessed September 2, 2015.
- US Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/Drugs/DrugSafety/ucm276251.htm. Accessed September 2, 2015
This article was originally published in our monthly issue of From the Front Lines – a monthly publication that shares best practices and medication-related challenges faced by “front line” staff in long-term care and post-acute (LTCPAC) facilities.